)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sartorius Stedim Biotech
Sartorius Stedim Biotech (DIM) investor relations material
Sartorius Stedim Biotech Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary22 Oct, 2026
Executive summary
9M revenue was €2,289.2m; operational growth was 7.8% in constant currencies excluding tariff compensation and 6.5% including it.
Recurring consumables remained the main growth driver; bioprocess equipment continued its positive trend, with growth across all regions.
Operating and free cash flow increased, while net leverage declined, supporting confidence in FY 2026 guidance.
Financial highlights
Underlying EBITDA rose 4.8% to €716m; underlying EBITDA margin increased to 31.3% from 31.1%.
Underlying net profit increased 9.4% to €349.6m; reported net profit rose 26.7% to €276.6m.
Q3 revenue was €762.1m, up 7.4% in constant currencies; underlying EBITDA increased 7.2% to €237.1m.
Outlook and guidance
FY 2026 constant-currency revenue growth guidance remains 6%–10%; operational growth excluding tariff effects is expected near the midpoint, while growth including compensation is expected in the lower half.
Underlying EBITDA margin is forecast slightly above 31%; net debt to underlying EBITDA is expected to be slightly above 2x.
CapEx-to-revenue guidance was refined to ~13%, below the prior-year 13.3%.
Customer tariff compensation could reduce revenue by up to €35m versus initial assumptions; refund applications totaled ~€35m, with €28m received by September.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sartorius Stedim Biotech
- Profitable H1 growth, margin expansion, and guidance confirmed despite tariff effects.DIM
Q2 2026 - Q1 2026 delivered strong sales and cash flow growth, with guidance reaffirmed amid volatility.DIMQ1 2026
- All resolutions passed as strong financial results and strategic growth plans were presented.DIMAGM 2026
- Targets 9–12% organic sales growth and margin expansion, fueled by innovation and efficiency.DIMCMD 2026
- Exceeded 2025 guidance with strong consumables growth; 2026 outlook sees margin expansion.DIMQ4 2025
- Strong H1 2025 growth in sales and margins, led by consumables; guidance reaffirmed.DIMQ2 2025
- Order intake and recurring business drove stable results and margins, with guidance confirmed.DIMQ3 2024
- Sales and profit declined, outlook revised down amid volatility and regional weakness.DIMQ2 2024
- 2024 guidance met with strong cash flow, robust margins, and moderate growth expected for 2025.DIMQ4 2024
Next Sartorius Stedim Biotech earnings date
Q4 202623 Feb, 2027
Sartorius Stedim Biotech
Next Sartorius Stedim Biotech earnings date
Q4 202623 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sartorius Stedim Biotech S.A. is a global supplier of biopharmaceutical equipment and services, specializing in the development of products used in the manufacture of vaccines, biologics, and cell-based therapies. The company offers a wide range of solutions, including bioreactors, filtration systems, and single-use technologies, aimed at optimizing and accelerating biopharmaceutical production processes. The company is headquartered in Aubagne, France, and its shares are listed on Euronext Paris.